By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MannKind Corporation 

28903 North Avenue Paine

Valencia  California  91355  U.S.A.
Phone: 661-775-5300 Fax: 661-775-2081


MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas:

  • First, we are continuing to execute the Technosphere® Insulin clinical trial program.
  • Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
  • Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.

    Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.

    With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.

    Last Updated: 04-01-2008

    Key Statistics

    Ownership: Public

    Web Site: MannKind
    Symbol: MNKD

  • Company News
    MannKind (MNKD) Renegotiates Debt With Dilution—What Does This Mean To Investors? 4/20/2017 5:47:01 AM
    MannKind (MNKD): White Elephant For Sale? 4/10/2017 5:59:36 AM
    Struggling MannKind (MNKD) Sells HQ for $17.3 Million 1/24/2017 6:34:20 AM
    Struggling MannKind (MNKD)'s New Strategy Includes Doubling Its Sales Force 1/19/2017 6:28:41 AM
    MannKind (MNKD) Selects Annodyne As Digital AOR; Redesigned Site Wins Award 12/27/2016 9:05:39 AM
    The Only Way Troubled MannKind (MNKD) Might be Able to Avoid Bankruptcy 10/26/2016 6:44:20 AM
    Annodyne Named Digital Agency Of Record For MannKind (MNKD) 10/17/2016 9:50:54 AM
    Embattled MannKind (MNKD) Rumored to Be Up For Sale Or Possible Bankruptcy 1/27/2016 7:22:46 AM
    MannKind (MNKD) Retracts Job Offer After Former Employer Insulet (PODD) Objects, Names Another New CEO 1/12/2016 7:02:52 AM
    After Months of Rumors, MannKind Corporation (MNKD) and Sanofi (SNY) Terminate Afrezza Deal 1/5/2016 7:44:46 AM